Lilly's Jaypirca (pirtobrutinib), the First-and-Only Approved Non-Covalent BTK Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated CLL/SLL

Oct 6, 2026 - 11:00
 0  0
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0